Pinned Tweet
▶️ Learn more about our ITO™ Platform, which integrates massive multimodal data, frontier AI models, and high-throughput lab automation to identify novel disease targets and design therapeutics better and faster than traditional approaches.
Read our featured publication in J. Med. Chem., “PEGASUS: Unlocking Polarity in Cell-Permeable Cyclic Peptides Using AI Models Built on Massively Parallel Biological Assays”: pubs.acs.org/doi/10.1021/acs…
Learn more about 1910’s flagship AI models:
PEGASUS™ Featured Publication in J. Med. Chem.: lnkd.in/etbvf5VH
CANDID-CNS™ Publication in JCIM: lnkd.in/gWn2fYiP
Read the media exclusive in GEN Edge: lnkd.in/eyr_qb9f
CANDID-CNS™ is our state-of-the-art AI model that offers a breakthrough approach to predicting blood-brain barrier penetration, particularly for bRo5 molecules.
Read the full publication in JCIM: pubs.acs.org/doi/10.1021/acs…
To Partner on CANDID-CNS™: [email protected]
CANDID-CNS™ is our state-of-the-art AI model that offers a breakthrough approach to predicting blood-brain barrier penetration, particularly for bRo5 molecules.
Published in JCIM: pubs.acs.org/doi/10.1021/acs…
Our founder @JenAsherPhD was featured in a spotlight on 5 women shaping AI x Bio — highlighting Jen's work at 1910, where we're building an AI-native biotech transforming drug discovery with our ITO™ Platform.
Read the article: techlifesci.com/p/five-women…
1910 retweeted
CANDID-CNS: AI Unlocks Stereochemistry and Beyond Rule of 5 to Predict CNS Penetration of Small Molecules #DrugDiscovery #DeepLearning
pubs.acs.org/doi/10.1021/acs…
@jeswcollins @fatal3rror @jenasherphd @1910_ai
#JCIM Vol65 Issue23 #PharmaceuticalModeling
1910 retweeted
1910 Unlocks Macrocyclic Peptide Drugs Using PEGASUS AI Model
PEGASUS generates permeable macrocyclic peptides, offering new promise for a modality that can combine the properties of a biologic in a pill
@jenasherphd @1910_ai
#AI #drugdiscovery #peptides
hubs.li/Q03ZRTp70
1910 retweeted
Today, @1910_ai is thrilled to announce the publication of PEGASUS™, a state-of-the-art AI model for de novo design and optimization of macrocyclic peptides.
▪️Paper: pubs.acs.org/doi/10.1021/acs…
▪️Press Release: businesswire.com/news/home/2…
▪️ BD: To partner on PEGASUS™, [email protected]
1910 retweeted
Exciting News! @1910_ai PEGASUS™ paper is now published in J Med Chem! This AI model can design macrocyclic peptides that maintain cell permeability, a major challenge for this emerging drug class!
Paper:
pubs.acs.org/doi/10.1021/acs…
Press Release:
businesswire.com/news/home/2…
.
This is what happens when AI meets deep scientific expertise. PEGASUS™ is transforming how the pharmaceutical industry approaches macrocyclic peptide drug discovery.
📄 Full paper: pubs.acs.org/doi/10.1021/acs…
📰 Press release: businesswire.com/news/home/2…
🤝 Partner: [email protected]
Celebrating 10 well-deserved promotions at 1910 as our team continues advancing the mission to Make Every Pharma Company an AI Company™. Congratulations, Liping, Jesse, Ify, Leerang, Reyal, Cole, Lakshmi, Francis, Mostafa and Sidharth.
1910 retweeted
Exciting News! @1910_ai CANDID-CNS™ paper is now published in JCIM! This AI model helps predict which drugs can cross the blood-brain barrier, a major challenge in drug discovery!
Paper:
pubs.acs.org/doi/10.1021/acs…
Press Release:
businesswire.com/news/home/2…















